Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breast cancer drug may throw patients off balance, study finds

NCT ID NCT06184074

Knowledge-focused Sponsor: Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at 76 postmenopausal women with breast cancer to see if aromatase inhibitors affect balance and fall risk. Half the women had been taking the drug for at least a year, the other half never took it. Researchers measured balance using special tests and questionnaires. The goal is to understand if these common drugs increase the chance of falling.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aromatase inhibitors
What this could lead to
If this study finds clear links, it could help doctors monitor balance issues in breast cancer patients on aromatase inhibitors and possibly reduce fall risk.
What could go wrong
This is a small, completed observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

76 people

The number who actually took part.

Started

Feb 2024

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Postmenopausal woman with breast cancer, between 40-70 years old

Ages

40 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Postmenopausal Woman * Between 40-70 ages * Stage 1-3 breast cancer * Chemotherapy treatment due to breast cancer (Last dosage at least 6 months ago) * Using an aromatase inhibitors for at least 1 year for group 1 * Never using an aromatase inhibitors at all for group 2 * Volunteers must sign and agree to participate in the study. Exclusion Criteria: * Stage 4 breast cancer * Having active chemotherapy * Older age patient (over 70 years old) * Using of steroid * Presence of diabetes mellitus that lasts longer than 3 years or insulin usage * Neuropathic complaints * Lack of vitamin B12 and thyroid dysfunction * Dn4 (dolour neuropathic 4 question) score of 4 and above * History of stroke * Presence of polyneuropathy diagnosis * Medication due to polyneuropathy diagnosis (gabapentin, pregabalin, duloxetine) * Loss of motor function in the lower extremity * Use of assistive devices for walking * Presence of vestibular disorder * Presence of cognitive impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aromatase inhibitors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aromatase inhibitors Balanced Breast cancer

Contacts and locations

Locations

  • Ece Küçük

    Istanbul, 34457, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.